Nattokinase vs. Statins: The Data Nobody Shared

A Fermented Soybean Enzyme Goes Viral on Joe Rogan

If your social media feed has recently informed you that a cheap enzyme from fermented soybeans can replace your statin prescription, you're not alone. A clip from the Joe Rogan Experience discussing nattokinase — a fibrinolytic enzyme derived from nattō, a traditional Japanese fermented soybean dish — has racked up hundreds of thousands of views. The central claim: a study of 1,062 people showed nattokinase dissolves arterial plaque and lowers cholesterol as effectively as statins, without the side effects.¹

The tweet that landed in my inbox came from Dr. Dawn Michael, a health freedom advocate with a large following, who asked the question millions of supplement enthusiasts are now repeating: "Why hasn't nattokinase replaced statins?"² The post pulled in over 250,000 views in hours, joining a chorus of influencer content that positions nattokinase as a natural cardiovascular miracle.

It's an appealing story. Statins are among the most prescribed drugs on Earth — and among the most resented. Muscle pain, fatigue, liver concerns, and a general suspicion of pharmaceutical companies have made "natural statin alternative" one of the most powerful phrases in supplement marketing. Nattokinase checks every box: ancient food tradition, enzyme rather than synthetic chemical, available without a prescription, and now apparently backed by a study with over a thousand participants.

So I did what I always do. I read the actual studies. All of them. And the story they tell is considerably more complicated than a podcast clip.

Two Very Different Drugs Doing Two Very Different Things

To understand why comparing nattokinase to statins is misleading from the start, you need to understand what each one actually does in your body.

Statins — atorvastatin, rosuvastatin, simvastatin — are HMG-CoA reductase inhibitors. They competitively bind to the active site of an enzyme your liver uses to manufacture cholesterol, with a binding affinity roughly 10,000 times stronger than the enzyme's natural substrate.³ The result: your liver produces less cholesterol endogenously, upregulates LDL receptors on its surface, and pulls more LDL particles out of your bloodstream. Statins reduce circulating LDL-C by 20–55%, depending on dose and drug. They also lower triglycerides, reduce vascular inflammation, improve endothelial function, and stabilize atherosclerotic plaques. Most importantly, they have been shown in dozens of large randomized controlled trials to reduce heart attacks, strokes, and cardiovascular death — the outcomes that actually matter.⁴

Nattokinase is a serine protease — a protein-cleaving enzyme — produced by Bacillus subtilis during soybean fermentation. Its primary action is fibrinolytic: it breaks down fibrin, the protein mesh that forms blood clots. It does this both directly and by converting plasminogen to plasmin, the body's natural clot-dissolving agent. Nattokinase also activates tissue plasminogen activator (t-PA) and inhibits plasminogen activator inhibitor-1 (PAI-1).⁵ Some laboratory evidence suggests it may also weakly inhibit HMG-CoA reductase — the same target as statins — but at a fraction of the potency.⁶

Here's the critical distinction: statins are lipid-lowering drugs first, with ancillary anti-inflammatory and anti-thrombotic benefits. Nattokinase is a fibrinolytic enzyme first, with weak and unproven lipid-modulating effects in humans. They are not interchangeable. Calling nattokinase a "natural statin" is like calling aspirin a "natural blood pressure medication" — it touches the cardiovascular system, but that's where the similarity ends.

1,062 Participants, Zero Randomization, and a Manufacturer Behind the Curtain

The study being shared across social media was published in Frontiers in Cardiovascular Medicine in 2022 by Chen et al. It enrolled 1,062 participants (491 male, 571 female, mean age 67.5) in China and followed them for 12 months while they took nattokinase at 10,800 FU per day — a dose roughly five times higher than what most supplements on the market provide.¹

The reported results were eye-catching: 66.5–95.4% of participants showed improvement in carotid plaque size. Total cholesterol, LDL-C, and triglycerides declined. HDL-C increased by 15.8%. Carotid intima-media thickness — a marker of atherosclerosis — improved.

Now here's what the viral posts don't mention.

This is not a clinical trial. It is a retrospective analysis with no control group, conducted largely by employees of the supplement manufacturer. Without randomization and a placebo arm, you cannot distinguish the effects of nattokinase from natural variation, dietary changes, regression to the mean, or the placebo effect. The fact that a corrigendum was needed within months of publication doesn't inspire additional confidence.

And there's a dose problem that matters enormously for consumers: the study used 10,800 FU per day and explicitly found that 3,600 FU/day was ineffective at lowering lipids or suppressing atherosclerosis.¹ The vast majority of nattokinase supplements on Amazon and in health food stores provide 2,000 FU per capsule. If you're taking the standard dose, you're getting less than one-fifth of what the study that's going viral actually tested.

NAPS: The Three-Year Trial That Found Nothing

If you want to know what nattokinase actually does in a rigorous clinical setting, there is exactly one study that meets the bar: the Nattokinase Atherothrombotic Prevention Study, or NAPS, published in Clinical Hemorheology and Microcirculation in 2021.⁷

NAPS was everything the Chen study was not: double-blind, placebo-controlled, randomized, and conducted at UCLA with funding from the National Science Foundation and the American Heart Association — not a supplement manufacturer. It enrolled 265 healthy individuals with a median age of 65.3 and followed them for a median of three years — the longest nattokinase RCT ever conducted.

The results were unambiguous: nattokinase at 2,000 FU per day had no measurable effect on atherosclerosis progression. No change in arterial thickening. No change in arterial stiffness. No change in blood pressure. No change in labs.⁷

This is the study that should be going viral. It's the one designed to minimize bias, funded by independent scientific organizations, conducted at a world-class research institution, and followed participants for years rather than months. And it found nothing.

Proponents will argue that 2,000 FU is too low a dose. That's a fair critique — and it highlights another problem: there is no consensus on what dose of nattokinase actually works in humans, and the dose that the viral study used (10,800 FU) has never been tested in a randomized, placebo-controlled trial. We're being asked to accept that a specific dose works based on a manufacturer-funded observational study, while the only rigorous trial of a standard dose found no benefit.

There is also an 82-participant study from 2017 by Ren et al. that directly compared nattokinase (6,000 FU/day) to simvastatin (20 mg/day) over 26 weeks.⁸ It reported that nattokinase reduced carotid plaque area by 36.6% compared to simvastatin's 11.5%. This is the study most often cited when someone claims nattokinase "beats statins." But it was unblinded, had no placebo group, and produced a paradoxical result: simvastatin achieved greater lipid reduction, yet nattokinase showed more plaque regression. That's mechanistically inconsistent and strongly suggests methodological noise rather than a real treatment effect.

Six RCTs, 546 Patients, and a Modest Blood Pressure Drop

The most comprehensive synthesis of nattokinase evidence is a 2024 systematic review and meta-analysis published in Reviews of Cardiovascular Medicine, which pooled data from six randomized controlled trials involving 546 total participants.⁹

The results give nattokinase a narrow win — but not where its fans want it.

Blood pressure: nattokinase reduced systolic BP by 3.45 mmHg and diastolic BP by 2.32 mmHg. Both statistically significant. Clinically, this is comparable to cutting your sodium intake — modest, real, but not remotely equivalent to what antihypertensive medications or statins achieve.⁹

Lipids: no significant effect on total cholesterol. No significant effect on LDL-C. No significant effect on HDL-C. No significant effect on blood glucose.⁹ The meta-analysis confirmed what the NAPS trial found individually: at standard supplement doses, nattokinase does not meaningfully move your lipid panel.

An earlier RCT from 2008 published in Hypertension Research tested 86 participants with elevated systolic blood pressure and found a 5.55 mmHg reduction — modestly useful, but again, this is a blood pressure study, not a statin replacement study.¹⁰

A 2024 double-blind trial of 178 patients with stable coronary artery disease tested nattokinase combined with red yeast rice and found modest effects on blood pressure and lipids.¹¹ But red yeast rice itself contains monacolin K — which is chemically identical to lovastatin. So the combination study cannot isolate nattokinase's contribution from what is essentially a statin smuggled in through a supplement.

The Bleeding Risk Nobody Puts on the Label

Most nattokinase RCTs report a clean safety profile — no significant adverse events versus placebo.¹² A real-world observational study of 153 vascular patients taking nattokinase 100 mg/day found no adverse drug reactions.¹² Toxicology studies show it's nonmutagenic and nonclastogenic, with safety demonstrated at doses up to 1,000 mg/kg/day in rats.

But here's the problem: nattokinase is a fibrinolytic enzyme. It dissolves clots. And if you combine it with other drugs that thin your blood or prevent clotting, the risk math changes dramatically.

In 2008, a case report documented a patient on daily aspirin who added nattokinase at 400 mg/day. After seven days, the patient developed an acute cerebellar hemorrhage. MRI revealed pre-existing cerebral microbleeds — small vessel damage that nattokinase's fibrinolytic activity, combined with aspirin's antiplatelet effect, turned catastrophic.¹³

A separate case involved an elderly woman taking over-the-counter nattokinase with no other anticoagulants who died of internal bleeding.⁵

Nattokinase is classified as a dietary supplement under DSHEA, meaning it does not require FDA pre-market approval. There are over 280 brands sold in the United States alone, with minimal standardization across products.¹⁴ Dosing ranges wildly. Bioavailability — what percentage of oral nattokinase actually reaches your bloodstream in active form — is not well characterized.⁵ You are essentially trusting a supplement industry with a poor track record for quality control to deliver a fibrinolytic enzyme at the right dose, in the right form, without interactions your doctor doesn't know about.

No major cardiology organization — not the American Heart Association, not the American College of Cardiology, not the European Society of Cardiology — has issued a favorable position statement on nattokinase for primary or secondary cardiovascular prevention.¹⁵

A Supplement with a Blood Pressure Effect and a Statin Marketing Problem